A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 112 participants.

Also called NCT07311551

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 112 participants (planned count) (from the registry)
Sponsor
Bhavya Bhavya, MD (from the registry)
Registry
  • NCT NCT07311551
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07311551. Randomized; no masking; primary purpose treatment. Start 2025-12-24 (anticipated); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)
Intervention (Drug)
Dapagliflozin (10Mg Tab) along with standard medical therapy
Intervention (Drug)
Empagliflozin (25 Mg Tab) along with standard medical therapy
Lead sponsor
Bhavya Bhavya, MD (class: other)

Record details

Record id
cardio:ct-nct07311551
Content hash
1a3782daffe47698a2f6ca1dc63f196c2a2fdfe5bb786edfefffc0fffcf5fcb4